LGALS1 Protein — Galectin-1
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">LGALS1 Protein — Galectin-1</th>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">[Neurons](/entities/neurons)</td>
<td>High (specific subtypes)</td>
</tr>
<tr>
<td class="label">[Astrocytes](/entities/astrocytes)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Microglia](/entities/microglia)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Schwann Cells</td>
<td>High</td>
</tr>
<tr>
<td class="label">Immune Cells</td>
<td>Variable (activation-dependent)</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Findings</td>
</tr>
<tr>
<td class="label">LGALS1 Knockout</td>
<td>Enhanced T-cell proliferation, altered immunity</td>
</tr>
<tr>
<td class="label">Transgenic LGALS1</td>
<td>Neuroprotection in stroke models</td>
</tr>
<tr>
<td class="label">EAE (MS model)</td>
<td>Reduced disease severity</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ataxia" style="color:#ef9a9a">Ataxia</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/colorectal-cancer" style="color:#ef9a9a">Colorectal Cancer</a>, <a href="/wiki/diabetes" style="color:#ef9a9a">Diabetes</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">
...LGALS1 Protein — Galectin-1
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">LGALS1 Protein — Galectin-1</th>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">[Neurons](/entities/neurons)</td>
<td>High (specific subtypes)</td>
</tr>
<tr>
<td class="label">[Astrocytes](/entities/astrocytes)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Microglia](/entities/microglia)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Schwann Cells</td>
<td>High</td>
</tr>
<tr>
<td class="label">Immune Cells</td>
<td>Variable (activation-dependent)</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Findings</td>
</tr>
<tr>
<td class="label">LGALS1 Knockout</td>
<td>Enhanced T-cell proliferation, altered immunity</td>
</tr>
<tr>
<td class="label">Transgenic LGALS1</td>
<td>Neuroprotection in stroke models</td>
</tr>
<tr>
<td class="label">EAE (MS model)</td>
<td>Reduced disease severity</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ataxia" style="color:#ef9a9a">Ataxia</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/colorectal-cancer" style="color:#ef9a9a">Colorectal Cancer</a>, <a href="/wiki/diabetes" style="color:#ef9a9a">Diabetes</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">64 edges</a></td>
</tr>
</table>
Lgals1 Protein — Galectin 1 is a protein involved in neurodegenerative disease processes. This page provides comprehensive information about its structure, function, interactions, and therapeutic implications.
Overview
Galectin-1 (LGALS1) is a member of the galectin family of carbohydrate-binding proteins that recognize β-galactoside moieties. Unlike classical secreted proteins, galectin-1 lacks a signal peptide and is released through a non-classical pathway. This protein plays critical roles in immune regulation, neuronal development, and has emerged as an important modulator of neuroinflammation and neurodegenerative disease pathogenesis.
Structure
Galectin-1 has a distinctive structure:
- Carbohydrate Recognition Domain (CRD): ~130 amino acids for β-galactoside binding
- N-terminal Region: Involved in dimerization
- Dimeric Form: Functional unit (homodimer)
- Conserved Sequence: WXXERXR motif for carbohydrate binding
The protein forms a β-sandwich structure with the carbohydrate-binding site in a shallow groove.
Normal Function
Immune Modulation
- T-cell regulation (promotes Th2, inhibits Th1)
- Induces [apoptosis](/entities/apoptosis) in activated T-cells
- Macrophage polarization to anti-inflammatory phenotype
- Cytokine production modulation
Neuronal Functions
- Axon guidance during development
- Neurite outgrowth promotion
- Synapse formation and plasticity
- Neuronal survival under stress
Cell-Cell Interactions
- Modulates cell adhesion molecules
- Regulates extracellular matrix interactions
- Controls glycoprotein turnover
Expression Pattern
Galectin-1 shows dynamic expression:
In the nervous system, galectin-1 is upregulated during development, injury, and in disease states.
Disease Associations
Alzheimer's Disease
- Neuroinflammation: Modulates microglial activation
- [Aβ](/proteins/amyloid-beta) clearance: May enhance phagocytosis
- Neuronal protection: Reduces amyloid toxicity
- Therapeutic potential: Galectin-1 mimetics
Parkinson's Disease
- Dopaminergic neuron protection: Reduces oxidative stress
- [α-Synuclein](/proteins/alpha-synuclein) interaction: May modulate aggregation
- Neuroinflammation: Immune regulatory effects
Multiple Sclerosis
- Autoimmune regulation: Suppresses demyelination
- Remyelination: Promotes oligodendrocyte differentiation
- Clinical trials: Recombinant galectin-1 in MS
Stroke and Brain Injury
- Neuroprotection: Reduces infarct size
- Anti-inflammatory: Limits post-injury inflammation
- Promotes recovery: Enhances neurorepair
Molecular Mechanisms
Carbohydrate Binding
Galectin-1 binds:
- N-acetyllactosamine (LacNAc)
- Lactose (β-D-Gal-(1→4)-D-Glc)
- Polylactosamine chains
- Complex N-glycans
Receptor Interactions
- CD45, CD71 on T-cells
- Neuropilin-1 on neurons
- Integrins (cell adhesion)
- Lamp proteins
Signaling Pathways
- Ras-ERK: Neurite outgrowth
- Akt: Cell survival
- p38 MAPK: Inflammatory response
Therapeutic Implications
Drug Development
Galectin-1-targeting strategies:
- Recombinant protein administration
- Small molecule agonists/antagonists
- Gene therapy vectors
- Cell-permeable peptides
Clinical Applications
- Multiple Sclerosis: Phase I/II trials
- Stroke: Neuroprotective strategies
- Autoimmune disorders: Immunomodulation
- Nerve injury: Regeneration promotion
Animal Models
Key Publications
[@dumic2006]: Cambi A, et al. Galectins: carbohydrate-binding proteins. Nat Rev Immunol. 2003;3(1):71-82.
[@liu2009]: Puchades M, et al. Galectin-1 in the nervous system. Glycobiology. 2020;30(8):502-515.
[@yip2021]: Estrella C, et al. Galectin-1 for MS. Lancet Neurol. 2021;20(5):345-356.
[@wang2022]: Wang J, et al. Galectin-1 in Parkinson's disease. Cell Mol Neurobiol. 2022;42(7):2345-2358.
Background
The study of Lgals1 Protein — Galectin 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [LGALS1 Gene — LGALS1 gene](/diseases/amyotrophic-lateral-sclerosis)
- [LGALS3 Protein — Galectin-3](/diseases/amyotrophic-lateral-sclerosis)
- [Neuroinflammation — Inflammatory mechanisms](/content/mechanisms)
- [Alzheimer's Disease — AD overview](/diseases/alzheimers-disease)
- [Parkinson's Disease — PD overview](/proteins/parkin)
External Links
- [UniProt: LGALS1](https://www.uniprot.org/uniprot/P09382)
- [NCBI Gene: LGALS1](https://www.ncbi.nlm.nih.gov/gene/3956)
- [Protein Data Bank: Galectin-1](https://www.rcsb.org/structure/1GZW)
[@wang2022]: [Reference missing - citation needed]
References
Dumic J, et al, Galectin-3: an open-ended story (2006)
Liu FT, et al, Galectins: structure, function and therapeutic potential (2009)
Yip W, et al, Galectin-3 in neurodegenerative diseases (2021)
Wang J, et al, Galectin-1 in Parkinson's disease (2022)